BOCA RATON, Fla., July 20, 2016 /PRNewswire/ -- CSL Plasma Inc., one of the world's largest collectors of human plasma, has set a new giving record for their donation to the Immune Deficiency Foundation (IDF). During the months of April through June, CSL Plasma donors and employees raised over $118,000.
"Year after year, CSL Plasma demonstrates their incredible commitment to people with primary immunodeficiency diseases by raising record funds for the Immune Deficiency Foundation," said Marcia Boyle, IDF President and Founder. "A contribution like this was raised because of the hard work and generosity of many—from center staff, plasma donors and local communities across the country. The funds will support the vital resources that we provide to thousands of individuals and families living primary immunodeficiency. We are humbled by this gift and proud that CSL Plasma is a long-time partner, participating in the IDF Plasma Partners Program for 10 years."
Funds raised for the IDF will be used to fund support services, education, and research for individuals with primary immunodeficiencies (PI) and their families. Last year CSL Plasma raised $100,975; this year's total represents a 17%+ increase. Since 2011, CSL Plasma has donated over $499,000 to support the IDF vision and mission.
Michael Deem, Senior Vice-President and General Manager for CSL Plasma stated, "I am proud to see CSL Plasma employees living our promise of giving back and donors participating in this great cause. CSL Plasma is pleased to be a partner that has now spanned a decade."
CSL Plasma U.S. centers, logistic centers, laboratory and corporate offices in Boca Raton all joined in on the fundraising activities during the months of April, May and June. The IDF theme of 'Think Zebra' provided excitement and visual appeal as all locations were decorated with a safari and zebra décor. The reason for this theme is that the PI community often identifies with zebras. As noted by Sonya Williams, Senior Manager of Corporate Communications and Community Relations for CSL Plasma, "In medical school, many doctors learn the saying, 'when you hear hoof beats, think horses, not zebras' and are taught to focus on the likeliest possibilities when making a diagnosis, not the unusual ones." IDF says that patients with PI are like the zebras of the medical world.
About CSL Plasma Inc.
CSL Plasma, headquartered in Boca Raton, Florida, upholds a tradition of innovation and excellence. As a leader in plasma collection, we are committed to excellence and innovation in everything we do. Our work ensures that tens of thousands of people are able to live normal, healthy lives. We are committed to our work because people's lives depend on us. CSL Plasma is a division of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia employs more than 16,000 people with operations in more than 30 countries. For more information about CSL Plasma, including eligibility requirements, please go to www.cslplasma.com.
About CSL Behring
CSL Behring is a global biotherapeutics leader, which is driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. For more information about CSL Behring visit www.CSLBehring.com or follow us at www.Twitter.com/CSLBehring.
If you would like to know more about PI or to donate direct, go to www.primaryimmune.org.
Media Contact:
Robert Mitchell
CSL Plasma
561.912.3010
Logo - http://photos.prnewswire.com/prnh/20150917/267581LOGO
SOURCE CSL Plasma Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article